Menu
Not yet recruiting NCT07615894

WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I)

Phase I Interventional Advanced Solid Tumors Malignant Pleural Effusions Malignant Ascites

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: WSK-IM02.
Who it may be relevant to
Registry conditions: Advanced Solid Tumors, Malignant Pleural Effusions, Malignant Ascites. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Single-Arm, Open-Label, Prospective Phase I Clinical Study to Evaluate the Safety and Preliminary Efficacy of WSK-IM02 in Patients With Advanced Solid Tumors Complicated by Malignant Pleural or Peritoneal Effusions

Overview

This is a prospective, single-center, interventional, phase I, dose-escalation, single-arm study designed to evaluate the safety, tolerability, and preliminary efficacy of intrapleural/intraperitoneal infusion of WSK-IM02 in patients with advanced solid tumors complicated by malignant pleural or peritoneal effusions who have failed standard of care.

Interventions

  • Biological WSK-IM02
    WSK-IM02 is an injectable pMVA-1 lipid complex

Primary outcome measures

  • adverse events (AE) [Time frame: up to 28 days]
Secondary outcome measures (3)
  • Objective response rate (ORR) [Time frame: up to 12 months]
  • Progression-free survival (PFS) [Time frame: up to 12 months]
  • Overall survival (OS) [Time frame: up to 12 months]

Eligibility criteria

Inclusion criteria

  • Age ≥18 years and ≤75 years.
  • Voluntarily sign informed consent form.
  • Patients with histologically or cytologically confirmed advanced solid tumors.
  • Histologically or cytologically confirmed malignant pleural/peritoneal effusion requiring drainage; or, in the absence of histologic/cytologic evidence, pleural effusion with clear imaging evidence of malignant pleural/peritoneal lesions on chest/abdominal CT and diagnosed as malignant pleural/peritoneal tumor in clinical practice.
  • Have received standard systemic therapy and developed clinical symptoms of serous cavity metastasis.
  • ECOG performance status: 0-2 points. Patients with ECOG 3 may be included if, in the investigator's judgment, removal of the effusion could improve the score to 2 or above.
  • Life expectancy ≥3 months.
  • Adequate major organ function.
  • Able to tolerate thoracentesis/abdominocentesis and catheter placement, or already have a functional thoracic/abdominal drainage catheter in place, and agree to receive study drug treatment via this route.

Exclusion criteria

  • Participation in any other interventional clinical trial within 4 weeks prior to the first dose of study drug.
  • Received local intracavitary therapy for pleural/peritoneal effusion (excluding diagnostic or symptom-relieving puncture/drainage) within 2 weeks prior to the first dose of study drug.
  • Received extra-thoracic/extra-abdominal radiotherapy within 2 weeks prior to the first dose of study drug, or received radical radiotherapy to pleural/peritoneal or pulmonary/abdominal lesions within 8 weeks prior to enrollment (palliative radiotherapy to chest/abdomen is permitted).
  • Underwent major thoracic or abdominal surgery within 4 weeks prior to the first dose of study drug and not fully recovered, or planned to undergo elective major surgery during the study period.
  • Any toxicity from prior anti-tumor therapy has not recovered to ≤ Grade 1 at the start of study treatment.
  • Symptomatic, uncontrolled central nervous system (CNS) metastases or leptomeningeal metastases that, in the investigator's judgment, make the patient unsuitable for enrollment.
  • Known human immunodeficiency virus (HIV) infection, active hepatitis B, active hepatitis C, or active syphilis infection.
  • Active, uncontrolled infection requiring systemic antibiotics, antivirals, or antifungal therapy.
  • Pregnant or breastfeeding women.
  • Definite history of severe mental or cognitive disorders that, in the investigator's opinion, may affect study compliance or safety assessment.
  • Presence of any active autoimmune disease, or history of autoimmune disease requiring systemic immunosuppressive therapy (topical glucocorticoids or inhaled/intra-articular steroids are permitted).
  • Require systemic corticosteroids or other immunosuppressants within 2 weeks prior to the first dose of study drug, and expected to require long-term use during the study.
  • Have poorly controlled or severe cardiovascular disease.
  • Have poorly controlled metabolic disease or complete/severe gastrointestinal obstruction requiring intervention.
  • Hypersensitivity to the investigational drug, any of its excipients, liposomal formulations, or kanamycin.
  • Have had a major thromboembolic event within 6 months prior to the first dose, or have a clear bleeding tendency.
  • Active local infection at the administration site.
  • Uncorrectable coagulation dysfunction that would pose a high risk for thoracentesis/abdominocentesis or catheter placement.
  • Have any other concurrent, serious, and/or uncontrolled medical condition.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • West China Hospital of Sichuan University — Chengdu

Identifiers

NCT: NCT07615894 · WSK IM02-2

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗